TCLF 2020

Program

Congress

Disease Area

Publication Type

Presentations

Brentuximab Vedotin | Lymphoma

Exploratory analysis of retreatment with brentuximab vedotin (BV) after frontline treatment with BV and CHP (A+CHP) for patients with CD30+ PTCL

View/Download

Brentuximab Vedotin | Lymphoma

Exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in frontline treatment of pts with CD30+ PTCL (ECHELON-2): impact of consolidative SCT

View/Download

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Privacy Policy
Legal Notices
Contact Us

This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy

Welcome to Seagen Medical Affairs

Seagen Medical Affairs is a resource for accurate, balanced, and evidence-based information related to Seagen products and research. The information provided on this site is in response to unsolicited requests for information from healthcare professionals.

This website is intended for US healthcare professionals only. Please confirm the option below that best describes you:

US Healthcare Professional

Non-US Healthcare Professional

Non-Healthcare Professional

You are now leaving Seagen Medical Affairs

This link will take you to a website that is not owned or controlled by Seagen. Seagen makes no representation regarding the accuracy of the information on this site. Your use of third-party websites is subject to the terms and conditions of use for these sites.

Accept. I understand I am leaving this site.

I understand that I am leaving this site

Cancel. I want to stay on the Seagen Medical Affairs site.

Keep me at Seagen Medical Affairs site